论文部分内容阅读
目的:观察尿多酸肽(CDA-2)治疗低/中危骨髓增生异常综合征(MDS)的贫血改善疗效。方法:确诊为低/中危-Ⅰ的MDS患者12例,接受连续2～4疗程以CDA-2为主的治疗后,观察总疗效、贫血改善的疗效及不良反应。结果:12例患者中,6例贫血改善,其中显效4例(33.3%),有效2例(16.7%),总有效率50.0%,平均起效时间30.1 d;不良反应包括轻度恶心6例(50.0%),轻度水肿4例(33.3%)。结论:以CDA-2为主的治疗对改善低/中危-ⅠMDS患者的贫血有较好的疗效,不良反应较轻。
Objective: To observe the effect of CDA-2 on anemia of low / moderate myelodysplastic syndrome (MDS). Methods: Twelve patients with MDS diagnosed with low / moderate risk-Ⅰ were treated with CDA-2 for 2 ~ 4 consecutive courses of treatment, and the curative effect and adverse reactions were observed. Results: Of the 12 patients, 6 patients improved anemia, of which 4 patients (33.3%) were effective, 2 patients (16.7%) effective, the total effective rate was 50.0% and the mean effective time was 30.1 days. Adverse reactions included mild nausea (50.0%), mild edema in 4 cases (33.3%). Conclusion: CDA-2-based therapy is effective in improving anemia in patients with low / moderate risk-Ⅰ MDS, with mild adverse reactions.